Evidence-Based Criteria Supporting Early Discharge for Pediatric Patients With Osteosarcoma Receiving High-Dose Methotrexate: A Retrospective Chart Review

Erin Armideo, CRNP, MSN, BSN, RN, CPON, Shannon Froio, BSN, RN, Meredith Johnson, CRNP, MSN, BSN, RN, Alison Tardino-Gingrich, CRNP, MSN, BSN, RN, and Elizabeth Froh, PhD, RN

Purpose: The purpose of this study is to describe the outcomes following the implementation of an early discharge protocol for pediatric patients with osteosarcoma receiving high-dose methotrexate (MTX) to determine if the protocol safel...

Tazemetostat: EZH2 Inhibitor

Rachael Straining, PharmD, and William Eighmy, PharmD

Epigenetic regulation is a novel approach to cancer treatment. Inhibition of enhancer of zeste homolog 2 (EZH2) is a method to provide targeted epigenetic regulation. Tazemetostat is a first-in-class targeted epigenetic regulator that sp...

Uterine Leiomyosarcoma

Katherine L. Byar,(1) MSN, APN, BC, BMTCN®, and Tricia Fredericks,(2) MD, MPH

Leiomyosarcoma (LMS) is the most common soft tissue sarcoma in adults and can occur in any part of the body. Uterine leiomyosarcoma (uLMS) is the most common location for LMS, making up 2% to 5% of all uterine malignancies. It is an aggr...

Retroperitoneal Liposarcoma: An Unusual Presentation of a Rare Cancer

Jennifer L. Spicer, MA, PA-C

Retroperitoneal liposarcomas (RLPS) are rare tumors that have variable clinical behavior and complex treatment strategies based on presentation, histopathology, and genomics. Early identification is critical, and complete surgical resect...

Sarcoma: Disease Overview and Treatment Updates

Presented by Cissimol Joseph, APRN, AOCNP®, and Prachee Singh, PA-C, MS

During JADPRO Live Virtual 2020, Cissimol Joseph, APRN, AOCNP®, and Prachee Singh, PA-C, MS, highlighted the clinical features and diagnostic workup of soft-tissue sarcoma and presented on a multidisciplinary approach to treatment planni...

Optimizing Outcomes for Patients With Soft-Tissue Sarcoma Through the Multidisciplinary Medical Oncology/Radiation/Surgical Team Approach

A multidisciplinary team can help improve the outcomes of patients with any cancer, but particularly so for patients with soft-tissue sarcomas, as discussed at JADPRO Live. During this presentation, MD, PA, and NP colleagues from Moffitt...

Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma

Abstract Olaratumab is a monoclonal antibody that recently received accelerated approval for the treatment of advanced soft-tissue sarcomas in combination with doxorubicin for a histologic subtype in which anthracycline-containing regim...

Anisocoria and an Array of Neurologic Symptoms in an Adult With Ewing Sarcoma

Case Study Ms. M, a 50-year-old female, reported a progressive 2-year history of sacral pain that became severe in the 2 to 3 months prior to her diagnosis of Ewing sarcoma (ES) and was initially evaluated by her gynecologist. Her prese...

Case Study of a Young Adult With Ewing Sarcoma

Case Study Maria was a 23-year-old woman who initially presented with a 1-year history of pain in the left heel. Over time, the pain had progressively worsened. Eventually, her foot had swollen, and she had difficulty walking, which req...

Pazopanib: Approval for Soft-Tissue Sarcoma

Pazopanib (Votrient), an oral, multitargeted tyrosine kinase inhibitor that was previously approved by the FDA for advanced renal cell carcinoma, recently gained FDA approval for select patients with soft-tissue sarcoma as well. Learn mo...